Kanzo
Online ISSN : 1881-3593
Print ISSN : 0451-4203
ISSN-L : 0451-4203
Short Communications
A pilot study of triple therapy with telaprevir 1500 mg, peginterferon and ribavirin for elderly HCV patients
Tasuku HaraNorio AkutaTaito FukushimaYuya SekoYusuke KawamuraHitomi SezakiTetsuya HosakaMasahiro KobayashiSatoshi SaitoYoshiyuki SuzukiFumitaka SuzukiYasuji AraseKenji IkedaMariko KobayashiHiromitsu Kumada
Author information
JOURNAL FREE ACCESS

2012 Volume 53 Issue 10 Pages 624-626

Details
Abstract
We evaluated the triple therapy with telaprevir (TVR) 1500 mg, peginterferon and ribavirin treatment during 12 weeks on-treatment for elderly patients with chronic hepatitis infected HCV genotype 1b. 17 patients received triple therapy with TVR 1500 mg, and the other 4 patients received TVR 2250 mg. HCV-RNA negative rates in TVR 1500 mg could be achieved 100% after 8 weeks. Furthermore, decreases of hemogulobin levels in TVR 1500 mg were significantly milder than those in TVR 2250 mg. These results suggest that triple therapy with TVR 1500 mg might be one of safety and useful treatment regimens for elderly HCV patients.
Content from these authors
© 2012 The Japan Society of Hepatology
Previous article Next article
feedback
Top